Form 4: United Therapeutics Insider Trades Common Stock

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on May 1, 2026, under a Rule 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO and Director of United Therapeutics Corp, engaged in several transactions on May 1, 2026.
• These transactions included the acquisition of 9,500 shares of common stock at a price of $146.03 per share, and the disposition of various amounts of common stock at prices ranging from $565.62 to $572.67 per share.
• The acquisition of shares was through the exercise of stock options.
• All transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• This plan is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt beneficially owns 40,513 shares directly and a significant number of shares indirectly through various trusts and by spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting routine insider transactions executed under a pre-established plan, with no immediate indication of significant positive or negative company performance.

Positives

• The exercise of stock options and subsequent sale of shares indicates a potential realization of gains from prior equity awards.
• The use of a Rule 10b5-1 trading plan demonstrates a structured and pre-planned approach to managing personal stock holdings, which can be viewed positively for corporate governance and insider trading compliance.
• The reporting person continues to hold a substantial number of shares indirectly, suggesting ongoing commitment to the company.

Negatives

• A significant number of shares were disposed of, which could be interpreted as a reduction in direct beneficial ownership by a key executive.
• The weighted average sale price of $565.78 to $572.67 per share is substantially higher than the exercise price of $146.03, indicating a profitable sale for the reporting person, but also a reduction in the number of shares held.

Risks

• The ongoing Rule 10b5-1 plan allows for continued sales of stock, which could lead to further reductions in the reporting person's direct holdings if market conditions remain favorable for sales.
• The plan's continuation is tied to option expiration and a fixed date, implying a potential for significant stock movement within a defined timeframe.

Future Outlook

The Rule 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. This indicates potential for further transactions within this period.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a CEO is common practice to diversify holdings or manage personal finances in a pre-determined manner, mitigating concerns about insider trading during periods of price volatility.

Stakeholder Impact

• Shareholders: The disposition of shares by a key executive could be perceived negatively if not understood within the context of a pre-arranged trading plan. However, the plan itself is a governance mechanism designed to prevent market manipulation.
• Employees: The transactions do not directly impact employee stock options or benefits, but the executive's stock activity can influence overall employee morale.
• Creditors: No direct impact is indicated.

Next Steps

• Continue to monitor Form 4 filings for further transactions by Martine A. Rothblatt under the Rule 10b5-1 plan.
• Observe the company's stock performance and any related news that might influence the execution of the remaining options or the continuation of the trading plan.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Rule 10b5-1, United Therapeutics Corp, UTHR, Beneficial Ownership, Common Stock, Executive Transactions, SEC Filing